Topic:

Emerging Markets

Latest Headlines

Latest Headlines

India crowdsources whistleblowing with website, mobile app

India has given consumers a way to complain about the availability or pricing of drugs. By providing an online portal and mobile app through which consumers can vent their grievances, Indian authorities are trying to turn the country's vast population into a disaggregated army of whistleblowers.

Merck KGaA to tap Oschmann as new CEO, sources report

Merck KGaA is the latest company to join Big Pharma's recent round of executive musical chairs. The German drugmaker is promoting deputy chief executive Stefan Oschmann to replace current CEO Karl-Ludwig Kley as the company's top dog.

Sanofi's Shantha ready to supply 37 million doses of long-delayed pentavalent jab

After rolling out its long-delayed Shan5 vaccine in November, Sanofi's Indian affiliate, Shantha Biotechnics, is ready to provide up to 37 million doses, having already started the process on Tuesday.

Gilead to require proof of citizenship to buy Sovaldi in poor countries

Not long after Gilead Sciences' high-priced hep C super drugs Sovaldi, and then combo drug Harvoni, hit the market, the California drugmaker struck deals with 11 generic drugmakers to make cut-rate versions available, and affordable, in 91 developing countries. But Gilead is not as generous as it might seem, Doctors Without Borders claims.

Vivo Capital doubles down to close $750M U.S.-China healthcare fund

Vivo Capital has closed an oversubscribed eighth fund at $750 million to invest in later-stage pharma and medical device companies in the U.S. and revenue-stage companies in greater China. That's precisely twice the size of its prior fund, which closed at $375 million in January 2012.

Malaysia's CCM Duopharma Biotech adds plants to compete better

A Malaysian drugmaker has bulked up its manufacturing capacity as it faces drugmakers from other countries building plants there to grab a piece of a market that is seeing the kind of growth hard to come by in other parts of the world.

Takeda transfers HPV vaccine rights as it continues globalization push

Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.

Glaxo plants a flag in Singapore with CEO Witty on hand

GlaxoSmithKline planted its flag in Singapore to build on a close relationship with the government of the wealthy city-state where CEO Andrew Witty worked and lived earlier in his career with the U.K. drugmaker.

Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck

Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline and Merck. Now, it's ready to make good on its promise.

China's Mindray jumps on acquisition rumor involving state-owned investment firm

The share price of China's Mindray Medical rose 16% last week on the New York Stock Exchange amid rumors that it will be taken over by private equity firms, including the country's state-owned investment company.